18-21 July 2018 Dublin
PB-001 | Platelet Chemokine Receptor CXCR7 Mediates an Anti-thrombotic and Anti-thromboinflammatory Effect | Madhumita Chatterjee | Received |
PB-002 | Ticagrelor Inhibits Platelet-induced Formation of Neutrophil Extracellular Traps | Iraklis C. Moschonas | Received |
PB-007 | Beta-1,4-galactosyltransferase 2 c.909C>T Gene Variant Is Predictive of On-clopidogrel Platelet Reactivity | Tiphaine Belleville-Rolland | Received |
PB-008 | High On-treatment Platelet Reactivity (HTPR) on Clopidogrel but Not on Novel P2Y12 Antagonists in Patients with ACS Undergoing PCI - Single Centre Study | Ján Stako | Received |
PB-009 | Detection of Anthocyanins Effects to Alleviating Thrombotic Risks in Comparison to Aspirin | Almottesembellah Gaiz | Received |
PB-011 | Assessment of Clopidogrel Response in Patients with Prior Atherothrombotic Events | Zühre Kaya | Received |
PB-014 | Results of Platelet Aggregation Testing by Light Transmission Aggregometry using Drug Specific Agonists in Patients Taking Antiplatelet Therapy | Sandra Margetic | Received |
PB-017 | Impact of Time-to-treatment on Freedom-from-relapse for Steroid-Refractory Immune Thrombocytopenia | Prakash Vishnu | Received |
PB-018 | Guidance on the Diagnosis and Management of PT-VWD: A Project from the Platelet Physiology Subcommittee of the ISTH | Maha Othman | Received |
PB-019 | PK Simulation of Avatrombopag-induced Increases in Platelet Counts with Redosing in Patients with Thrombocytopenia and Chronic Liver Disease | Kavita Aggarwal | Received |
PB-020 | Exploratory Analyses of the Efficacy of Avatrombopag versus Placebo from 2 Phase 3 Studies Using Alternate Baseline Platelet Count Cohorts and an Alternate Secondary Efficacy Endpoint | Kavita Aggarwal | Received |
PB-021 | Influence of Preoperative Platelet Activity on Coagulation and Blood Loss in Large Orthopedic Surgery | Irina Antropova | Received |
PB-022 | Superiority of Avatrombopag to Placebo in Increasing Platelet Counts and Reducing Platelet Transfusions in Patients with Chronic Liver Disease-associated Thrombocytopenia Undergoing Scheduled Procedures - Pooled Analysis of 2 Randomized Phase 3 Studies | Kavita Aggarwal | Received |
PB-023 | Atypical Presentations of RUNX1 Associated Familial Platelet Disorder with Predisposition to Myeloid Malignancy (FPDMM) | Christopher Ward | Received |
PB-024 | Population PK/PD Modeling of Avatrombopag in Patients with Thrombocytopenia and Chronic Liver Disease - Guided Phase 3 Dose Selection | Kavita Aggarwal | Received |
PB-026 | Bloody Diarrhea with Thrombocytopenia in Male Children: Think of Wiskott Aldrich Syndrome | Deepti Suri | Received |
PB-027 | Pseudothrombocytopenia: Beyond Platelets Aggregates | Anália Carmo | Received |
PB-028 | Coagulation Abnormalities in Dengue and Dengue Hemorrhagic Fever Patients in Pakistan | Jawad Hassan | Received |
PB-030 | Acquired Platelet Function Defect and Moderate Cutaneous Bleeding in a Patient on Treatment with a Leukotriene Receptor Antagonist for Asthma | Marina Marchetti | Received |
PB-031 | Pelvic Hematoma Secondary to Glanzmann´s Thrombasthenia: A Case Report | Siong Leng Hon | Received |
PB-033 | Platelet´s Disorder in a Case of Chronic Lymphocytic Leukemia | Corrado Lodigiani | Received |
PB-035 | Dichotomous Cytosolic Mobilization of Calcium, Sodium and Potassium Ions during Procoagulant COAT Platelet Formation | Alessandro Aliotta | Received |
PB-036 | Emerging Value of Platelet Function Testing at Predicting the Risk of Recurrent Vascular Events and Outcomes after TIA/Ischemic Stroke: A Systematic Review of the Literature | Soon Tjin Lim | Received |
PB-037 | Lysis of Blood Cells by Arachidonic Acid Cause ADP-dependent Platelet Activation Responses in Platelet Function Tests using Whole Blood | Sofia Ramstrom | Received |
PB-038 | Assessment of Platelet Count Standardization in Platelet-rich Plasma for Platelet Function Testing by Light Transmission Aggregometry | Mason Dixon | Received |
PB-039 | Kinetic Application of Flow Cytometry for Patients with Unknown Bleeding Disorders: The Underestimated Value of Mepacrine | Georgi Manukjan | Received |
PB-040 | The Gp1ba-Cre Transgenic Mouse: A New Model to Delineate Platelet and Leukocyte Functions | Zoltan Nagy | Received |
PB-041 | The Fluidity of Platelet Membrane an Important Parameter for Platelet Function in Chronic Myeloproliferative Neoplasms Patients | Viola Maria Popov | Received |
PB-042 | The Effect of FXa on Platelet Activation, in vitro | Styliani Papadaki | Received |
PB-043 | Functional Validation of microRNA-126-3p as a Platelet Reactivity Regulator using Human Progenitor Cells | Alix Garcia | Received |
PB-044 | Assessment of Light Transmission Aggregometry on the Routine Coagulation Analyzer Siemens CS-2500 using CE-marked Agonists from Hyphen Biomed | Mathieu Fiore | Received |
PB-047 | Influence of Sample Platelet Count on Three Common Platelet Function Tests: A Comparative Study | Anna L. Södergren | Received |
PB-048 | Comparison of PAC-1 and a-fibrinogen Antibody Binding to Platelet Subpopulations | Anna L. Södergren | Received |
PB-049 | Assessment of Neonatal Platelet Granule Trafficking and Shear-induced Platelet Activation in Neonatal Peripheral and Cord Blood | Anh Ngo | Received |
PB-053 | Platelets Role in the Plasma Clotting is Not Limited to Providing a Lipid Surface | Anna Balandina | Received |
PB-054 | Stability of Platelet Function in Healthy Individuals over a One-year Period | Mark Roest | Received |
PB-055 | The Canine Platelet Secretome (CAPS): Proteomic Analysis of Thrombin-stimulated Release | Signe Emilie Cremer | Received |
PB-057 | Mean Platelet Volume Positively Correlates with Uterine Volume after Menopause, Except Myomas Presence | Bibiána Bajteková | Received |
PB-061 | Flow Cytometric Analysis of Platelet Function in Patients on Antiplatelet Therapy and Suspected Thrombocytopathy | Dana Huskens | Received |
PB-062 | Characterization of Platelet Function with Flow Cytometry for Bleeding Risk Evaluation in Hematological Disorders | Anastasia Ignatova | Received |
PB-065 | Usefulness of Optical Aggregometry and Flow Cytometric Studies as a Complementary Tools in Patients with Acquired Platelet Defects (APD) | Analia Sanchez-Luceros | Received |
PB-066 | Platelet Function in Polycythemia Vera and Primary Myelofibrosis Using Multiple Electrode Aggregometry | Nikolaj Skrřder Nytofte | Received |
PB-067 | Platelet to Lymphocyte Ratio was Significantly Lower for Slovak Postmenopausal Women Born from November to April, Except those with Leiomyoma | Bibiána Bajteková | Received |
PB-069 | A Novel Role of LASSBio-788 in Inhibiting NF-?B Mediated Signaling in Platelet of Hypercholesterolemic Rats: Would Be New Antiplatelet Agent? | Nadia Alice Vieira Motta | Received |
PB-070 | New Clinicopathologic Finding in a Patient with Acquired Amegakaryocytic Thrombocytopenia Treated with Thrombopoietin Receptor Agonist Therapy | eva hortas | Received |
PB-075 | Evidence of a Dominant Negative Effect of Gain-of-Function ITGB3 Mutations over Loss-of Function Mutations in Variant Glanzmann Thrombasthenia | Loredana Bury | Received |
PB-076 | Bleeding Diathesis Associated with Severe Acquired Platelet Dysfunction and Overproduction of Cyclic AMP in Two Patients with Hematologic Malignancies | Andrea Artoni | Received |
PB-077 | In-silico Prediction of Molecular Mass Distance Dependent Changes in Binding Energies between von Willebrand Factor and Platelet Membrane Glycoprotein (GP) Iba in Wild Type and G233V Mutant | Shinichi Goto | Received |
PB-079 | Investigation of Polymorphic Variations in Glutathione S Transferase Genes among Immune Thrombocytopenia Patients in Pakistan | Samina Naz Mukry | Received |
PB-081 | CD8 T Cell-mediated Platelet Clearance Does Not Occur via Traditional Cytotoxic Protein Killing | Cheryl Maier | Received |
PB-082 | Human Platelets Labeled at Multiple Biotin Densities: A Promising Approach for Monitoring in vivo Platelet Survival in Clinical Trials | Catherine Ravanat | Received |
PB-083 | Quantitative Alteration of Vesicle Associated miRs and RISC Complex Reflect Platelet Concentrate Molecular Pattern during Storage as Platelets Activity Model | Vasilii Kishenko | Received |
PB-084 | Improving Transfusion Safety by Implementing Platelet Bacterial Screening in a Resource-limited Country | Farheen Karim | Received |
PB-089 | Compensatory Effect of Fibrinogen in Patient with Bone Marrow Aplasia, Septic Shock and Severe Thrombocytopenia Guided by Thromboelastometry: A Case Report | Tomaz Crochemore | Received |
PB-090 | A Novel Murine Model of Immune Thrombocytopenia Induced by Immunized CD41 Knockout Mice | Xin Li | Received |
PB-092 | Effects of Bothrops jararaca Venom on Platelet Aggregation, Secretion and Protein synthesis | Marcelo L. Santoro | Received |
PB-095 | Janus Kinase 3 (JAK3)-dependent Signaling Is Critical to Ca2+-dependent Platelet Activation and Thrombus Formation | Mailin Manke | Received |
PB-098 | Role of Protease-activated Receptor 4 in Regulating Platelet Dense Granule Release | Tiffany Chu | Received |
PB-103 | S100A9 Activates Platelets via RAGE | Saskia von Ungern-Sternberg | Received |
PB-105 | Induced Apoptosis-like Changes Caused by Sirtinol, a Pharmalogic Inhibitor of Sirt1/2, in Human Platelets | Ram L. Mallick | Received |
PB-106 | Tumor Necrosis Factor Receptor Associated Factor 6 (TRAF6) in the Pathogenesis of Immune Thrombocytopenia | Elif Umit | Received |
PB-107 | Patients with Aortic Stenosis Have von Willebrand Factor Abnormalities and Aberrant Angiogenesis in BOEC | Soundarya Nivedita Selvam | Received |
PB-108 | High-dose Dexamethasone Alters the Increase in IL-16 Level in Adult Immune Thrombocytopenia | Xinyi Zuo | Received |
PB-109 | Progranulin Facilitates the Increase of Platelet Count in Immune Thrombocytopenia | Xinyi Zuo | Received |
PB-110 | The Aberrant Expression of microRNAs in B Lymphocytes of Patients with Immune Thrombocytopenia | Xi Jia | Received |
PB-111 | A Novel Model using Protein C-to-INR Ratio to Predict Short-term Mortality in Cirrhosis | Anupama Patil | Received |
PB-112 | Increased Cytotoxic Potential of CD8 T Cells in Patients with Immune Thrombocytopenia | John R Vrbensky | Received |
PB-113 | Gene Expression of Vanin-1 (VNN-1) in Egyptian Adults with Immune Thrombocytopenia (ITP): A Single Center Experience | Doaa El Demerdash | Received |
PB-115 | Real-life Bleeding Risk of Anti-factor Xa Direct Oral Inhibitors; Does Prothrombin Complex Concentrate Work? | Buddhika Badugama | Received |
PB-117 | Is the Profile of Patients with Intracranial Hemorrhage Changing? | Sarah Reeves | Received |
PB-120 | Noonan Syndrome and Bleeding Disorders: An Overview of Current Diagnostic Management | C.H. van Ommen | Received |
PB-121 | Long-Term Follow-up of Children on Prophylaxis for Severe Factor VII Deficiency in Lebanon | Roula A. Farah | Received |
PB-122 | Clinical Presentations and Diagnostic Algorithm of Neonatal FXIII-deficiency | Mehran Karimi | Received |
PB-123 | Effectiveness of Pediatric Bleeding Questionnaire in Hemorrhagic Disorders | Laura Villarreal Martinez | Received |
PB-124 | Surgical Management of Rare Factor Deficiencies | Erol Erduran | Received |
PB-127 | Plasma Profile of Platelet Auto-antibodies in Patients with Thrombocytopenia in Pregnancy | Wenhong Shen | Received |
PB-131 | Translation and Validation of the Pictorial Blood Loss Assessment Chart (PBAC) in Arabic | Ons Kaabia | Received |
PB-132 | Diagnosis Value of Screening Tools for Hemostasis Disorders in Women Consulting for Prolonged Menstruation with Normal Pelvic Exam | Ons Kaabia | Received |
PB-133 | Clinical Screening for Underlying Bleeding Disorder in Nigerian Women | Theresa Nwagha | Received |
PB-134 | Hemostasis Disorders in Tunisian Women with Non Organic Menorrhagia: A Case Control Pilot Study | Ons Kaabia | Received |
PB-135 | Improving the Gynaecological Management of Women with Bleeding or Thrombotic Disorders by Multi-professional Out-patient Care | Kathryn Mary Musgrave | Received |
PB-136 | A Woman´s Life-long Bleeding Condition: Diagnostic Dilemma and Expert Opinion | Rochelle Winikoff | Received |
PB-137 | Thrombocytopenia in Pregnancy: The Role of Hemostasis Laboratory for Diagnosis and Management of Acute Fatty Liver of Pregnancy | Giuseppe Rescigno | Received |
PB-139 | Does Hemophilia Slow Down the Development of Liver Fibrosis? | Marie-Astrid van Dievoet | Received |
PB-140 | Geno- and Phenotype Correlate in Porcine Model of von Willebrand Disease Type 1 and Type 3 | Hanna Allerkamp | Received |
PB-142 | Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B | Massimo Morfini | Received |
PB-148 | Circulating Biochemical Markers of Early Joint Bleeding: Validation Study in Humans | Narine Hakobyan | Received |
PB-152 | Whole F8 and VWF Gene Sequencing using Next-generation Sequencing for Mutation-negative French and Canadian Hemophilia A Patients | Fanny Lassalle | Received |
PB-153 | Within-patient Comparison of Treatment Patterns before and after Switching to rFIXFc: A Report from the UK National Haemophilia Database | Martin Scott | Received |
PB-154 | Arthropathy and Joint Replacement Surgery in Patients with Hemophilia A (PwHA) in the US | Anisha Patel | Received |
PB-155 | Extended Half-life Factor Concentrate Use for Patients with Moderate and Severe Hemophilia among ATHN-affiliated U.S. Hemophilia Treatment Centers | Stacy E. Croteau | Received |
PB-156 | Genetic Polymorphisms Contributing to the Pharmacokinetics of Factor VIII Concentrates | Massimo Morfini | Received |
PB-157 | Real World Data Analysis of US Claims Database on Coagulation Factor VIII Expenditures in Patients with Hemophilia A: Standard Half-life vs. Extended Half-life Products | Bartholomew Tortella | Received |
PB-158 | Measuring FIX-Activity of Nonacog Beta Pegol (N9-GP) in a One-stage Ellagic Acid Based Clot Assay on the ACL TOP 50 Series Instrument: A Two-site Study | Mary Doyle | Received |
PB-161 | Correlation of Factor Levels with Bleeding Phenotype in Non-severe Hemophilia | Ingrid Pabinger | Received |
PB-164 | Burden of Mild Hemophilia A: Systematic Literature Review | Eva Hortas | Received |
PB-165 | Realworld Health Care Expenditure and Dispensation of Extended and Standard Half-life Recombinant Factor IX Products in Hemophilia B Patients | Bartholomew Tortella | Received |
PB-168 | The Effect of Unmeasurable Endogenous Plasma Factor Activity Levels on Factor VIII Dosing in Patients with Severe Hemophilia A | Pierre Chelle | Received |
PB-171 | Are Current Therapeutic Strategies with Conventional Products Sufficient to Manage the Burden of Haemophilia in Italy? | eva hortas | Received |
PB-172 | Practical Considerations in Choosing a Cost-effective and-Efficient Solution for Prophylaxis in Haemophilia | Margit Serban | Received |
PB-179 | The Bone Disease in Haemophilia: The Role of von Willebrand Factor, Factor VIII and Thrombin | Stefano Lancellotti | Received |
PB-181 | Standardized Determination of FVIII Inhibitors with the Improved FVIII INH Kit | Lieselotte Wagner | Received |
PB-185 | Joint and Functional Assessment Following Secondary and Tertiary Prophylaxis in PWH who were Previously Receiving Episodic on Demand Factor Replacement Infrequently | Anupam Dutta | Received |
PB-187 | Epidemiological Survey and Audit of Socio-demographic Characteristics of Patients with Haemophilia and other Congenital Bleeding Disorders | Helen Okoye | Received |
PB-188 | Development of a FVIII Antigen Assay to Quantify B-domain Deleted FVIII Antigen in Human Plasma | eva hortas | Received |
PB-192 | Hemophilia A Subjects with an Intron-22 Inversion Mutation Show Robust T-cell Responses to Epitopes in Both the FVIII Heavy and Light Chain | Kathleen P. Pratt | Received |
PB-197 | Potential Clinical Trial Validation of Differential EPCR-dependent Activity by Eptacog Beta, a rhFVIIa Variant, in the Treatment of Bleeding in Hemophilia Patients with Inhibitors | Jonathan Ducore | Received |
PB-200 | Risk Modeling Inhibitor Development of Haemophilia A Patients in Australia | Sumit Parikh | Received |
PB-203 | Successful Eradication of Factor FVIII Inhibitor by Cyclophosphamide Treatment in a Patient with Acquired Haemophilia A - A Case Report | Sandra Margetic | Received |
PB-204 | Clinical Description and Laboratory Characterization of Heparin-like Substance Causing Bleeding | Jun Teruya | Received |
PB-206 | Skeletal and Cardiac Muscle Myosin Exert Procoagulant and Antifibrinolytic Effects | Julia Coleman | Received |
PB-210 | Platelet-nanocapsule Hybrids for On-demand, Targeted Delivery of Factor VIII in Hemophilia A Mice | Caroline E. Hansen | Received |
PB-211 | Annualized Bleeding Rates, the Current Favorite Clinical Endpoint in Hemophilia Trials: Pitfalls and Caveats | Christine Keipert | Received |
PB-214 | Tranexamic Acid Reduces Post-surgical Infection Rates via Direct Immune Cell Modulation | Dominik F. Draxler | Received |
PB-215 | ROTEMŽ or Conventional Hemostasis Test: Experience in Cardiac Surgery Setting | Isabelle Gouin-Thibault | Received |
PB-216 | A New, Hand-held, Multifunctional Coagulation Laboratory for Perioperative Monitoring | Seemantini Nadkarni | Received |
PB-218 | Monitoring Anticoagulation and Hemostasis in Cardiac Surgical Patients with a Drop of Whole Blood | Diane Malu Tshikudi | Received |
PB-219 | Short-term Recovery Pattern of Plasma Fibrinogen after Cardiac Surgery: A Prospective Observational Study | Gabor Erdoes | Received |
PB-221 | Classification of Surgical Bleeding Situations | Richard Kocharian | Received |
PB-222 | Recombinant Factor VIIa (NovosevenŽ) Utilization and Safety for Refractory Bleeding After Cardiac Surgery at a Large Academic Medical Center | Tania Ahuja | Received |
PB-224 | Thromboelastometry-guided Therapy for the Treatment of Hemorrhagic Shock in Postoperative of Vascular Surgery: A Case Report | Tomaz Crochemore | Received |
PB-225 | Analysis of Fresh Frozen Plasma Requirement in Post Cardiopulmonary Bypass Cardiac Surgery Patient Based on Standard Coagulation and Thrombelastography Tests in Hasan Sadikin Hospital, Bandung | Leni Lismayanti | Received |
PB-226 | Quality and Accuracy of Testing for von Willebrand Disease by North American Special Coagulation Laboratories from 2010 to 2017 | Jameel Abdulrehman | Received |
PB-227 | FXI-deficient Patients with Bleeding Phenotype Show a Spatio-temporal Propagation of Blood Coagulation Shorter and Slower than Normal | Debora Bertaggia Calderara | Received |
PB-228 | The FVIII: C Measurement of Extended Half-life Recombinant Factor VIII FC Fusion in Haemophilia A Patients | Annette Bowyer | Received |
PB-229 | Overassignment of Recombinant Wild Type (rwt) FIX Potency by a One-stage Method Indicated from Comparison with Chromogenic FXIa and TF/FVIIa Based Methods and through Discrepant Activation of rwt FIX and Plasma Derived (pd) FIX by Plasma Kallikrein (PK) | Steffen Rosén | Received |
PB-230 | Sensitive and Standardized TGA Measurement in Haemophilia Patients Using CeveronŽ Alpha TGA | Nikolaus B. Binder | Received |
PB-231 | Differences in FVIII Measurements of Plasma Spiked with AFSTYLAŽ Generated with One-stage Clotting Assay using Different Commercial APTT Reagents Compared with Chromogenic Method | Inge Vangenechten | Received |
PB-233 | Pre - analytical Variables - Sample Rejection in Hemostasis Laboratories | Lilia Brown | Received |
PB-234 | Thromboelastometry Profile in Critically Ill Patients: A Single-center, Retrospective, Observational Study | Tomaz Crochemore | Received |
PB-235 | Differences in Activity of Plasma Spiked with IDELVIONŽ Generated with One-stage Clotting Assay using Different Commercial APTT Reagents Compared with Chromogenic Method | Inge Vangenechten | Received |
PB-236 | Extended Half-life Factor VIII: From Biology to Patients´ Management Optimization | Andreas Perrier-Cornet | Received |
PB-237 | Evaluation of an Automated Chromogenic Assay for Measuring FVIII:C Levels in the Patients Affected by Hemophilia A | Cristina Novembrino | Received |
PB-238 | Underassignment of FIX Potency of rFIX-Albumin Fusion Protein (rFIX-HSA) by One Stage Methods Demonstrated in Studies on FXIa and FIXa Generation | Steffen Rosén | Received |
PB-239 | Correlation of FIX Activity Assays with Thrombin Generation | Lisa Florin | Received |
PB-243 | One Stage and Chromogenic Assays Discrepancy in the Estimation of Factor IX (FIX) Recovery. What is it that a Single Hemophilia Center Can and Cannot Do? | Jovan P Antovic | Received |
PB-244 | Comparison of Two One-stage Clotting Assays and One Chromogenic FIX Assay for Monitoring of IdelvionŽ Replacement Therapy | Lisa Florin | Received |
PB-245 | Levels of Coagulation Factors, Coagulation Inhibitors and TAFI Do Not Affect Global Hemostasis and Bleeding Phenotype in Patients with Hemophilia A | Jovan Antovic | Received |
PB-247 | The Effect of DDAVP on Thrombin Generation in Patients with Bleeding Disorders | Alexandra Agapidou | Received |
PB-249 | Comparison of Three Thromboplastin Reagents for International Normalized Ratio (INR) Measurement in Patients on Vitamin K Antagonist Therapy | Francois Depasse | Received |
PB-251 | External Quality Assurance (EQA) for the Rotem Sigma Thromboelastometry Device | Dianne Kitchen | Received |
PB-252 | Stored Calibration Curves Can Deliver Acceptable Accuracy and Precison on CS5100 Analysers | Anne Sermon-Cadd | Received |
PB-253 | Measurement of Immunoglobulins Anti VWF in Patients with Probable AVWS with an Enzyme-linked Immunosorbent Assay (ELISA) Using Platelet VWF as an Antigen | Analia Sanchez-Luceros | Received |
PB-254 | Performance Evaluation of Automated Thrombin Generation Measurement on CeveronŽalpha TGA | Lieselotte Wagner | Received |
PB-255 | Calibrations Performed in the Lab Fail to Correct Fibrinogen Quality Control Variability Generated by Different Reactant Batches | Felipe Guerrero | Received |
PB-257 | Variations in Automated Platelet Counts Occur Depending on the Principle Used for Cell Counting and on the Non-platelet Blood Cell Parameters | Ganesh Kumar Viswanathan | Received |
PB-258 | Accuracy and Precision of Point-of-Care International Normalized Ratio (INR) in Pediatric and Adult Patients with Liver Disease Pilot Study | Patricia Sachi Kawada | Received |
PB-259 | Clearance of Mouse VWF Propeptide Is Mediated by Stabilin-2 and Is Regulated by N-linked Glycan Expression | Orla Rawley | Received |
PB-261 | Expression of the SCARA5 Scavenger Receptor in the Human Kidney and Spleen May Regulate Clearance of VWF | Laura L Swystun | Received |
PB-262 | Diverse Inheritance of VWD Found in Type 3 U.S. Families in the Zimmerman Program | Pamela Christopherson | Received |
PB-264 | High Molecular Weight von Willebrand Factor Multimers in Cryoprecipitate Exceed that Found in a Commercial Concentrate | Meaghan Elizabeth Colling | Received |
PB-270 | Molecular Analysis and Bleeding Phenotype of Seven Severe FV-deficient Patients from Pakistan | Munira Borhany | Received |
PB-271 | Rare Bleeding Disorders in Pakistan: An Update | Munira Borhany | Received |
PB-272 | Functional Polymorphisms of the von Willebrand Factor Gene in Patients with Mild to Moderate Bleeding Tendency and Low or Normal von Willebrand Factor Antigen or von Willebrand Factor Ristocetin Cofactor | Stefanie Hofer | Received |
PB-273 | Comparison of a von Willebrand Factor Fully-automated Chemiluminescent Assay Panel for von Willebrand Disease Diagnosis to and Historical Classification | Luciano Baronciani | Received |
PB-275 | Correction of Factor XI Deficiency by Liver Transplantation for Secondary Sclerosing Cholangitis | Corinne Frere | Received |
PB-276 | Intense Exercise Increases von Willebrand Factor and Factor VIII Levels in Well-trained Athletes | Paraskevi Spatharaki | Received |
PB-277 | Prevalence of von Willebrand Disease among Nigerian Youths in Ibadan South-Western Nigeria | Wuraola Shokunbi | Received |
PB-278 | Impact of Mitral Valve Clip Procedure on Indices of Acquired von Willebrand Syndrome | Joseph Blackshear | Received |
PB-279 | Comparative Study of Single Nucleotide Polymorphisms (SNPs) in the Exon 28 of the VWF between Healthy Donors, VWD2M (with p.E1549K and p.R1374C) and VWD2B Patients (with p.R1308C and p.V1316M) in a Single Center in Argentina. Preliminary Report | Analia Sanchez-Luceros | Received |
PB-280 | Genotyping of Five Patients with Severe Inherited Factor X (FX) Deficiency from Pakistan: Identification of Two Novel Mutations | Munira Borhany | Received |
PB-282 | Discrepant von Willebrand Factor (VWF) Activity Levels in Two Unrelated von Willebrand Disease (VWD) Patients | Mackenzie Bowman | Received |
PB-284 | Are Iranian Patients with von Willebrand Disease Type 2N Properly Differentiated from the Ones with Mild/Moderate Hemophilia A and Do They Receive Appropriate Treatment? | Asghar Seidi Zadeh | Received |
PB-285 | Polyphoshate Nanoparticles Slow Down the Clotting of Fibrinogen and Increase the Lytic Stability of Fibrin | Miklós Lovas | Received |
PB-286 | Alternative Complement Pathway Inhibits Fibrinolysis in an in-vitro Whole Blood Model | Jason Samuels | Received |
PB-290 | Novel Fibrinogen Missense Mutations in Patients with Fibrinogen Defects | Elvira Grandone | Received |
PB-293 | Increased Fibrinolysis as a Specific Marker of Poor Outcome after Cardiac Arrest | Michael Schwameis | Received |
PB-295 | Euglobulin Lysis Time (ELT) Behaviour in Patients Wwith Abnormal Clot Solubility Test (CST) | Lucia Remotti | Received |
PB-296 | Association between Use of Recombinant Tissue Plasminogen Activator and In-hospital Mortality and 30-day Readmission among Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Retrospective Cohort Study | Joshua Brown | Received |
PB-297 | Staphylokinase Potentiates Thrombolytic Effect of Single Chain Pro-urokinase in Plasma Milleu in vitro | Roza Aisina | Received |
PB-298 | Local Ultrasound-facilitated Thrombolysis in Pulmonary Embolism: First Dutch Experience and Retrospective Comparison with Systemic Thrombolysis | Maria Adriana de Winter | Received |
PB-302 | Clot Formation Assessment in Septic Patients with Cancer using a Time-based Parameter from the ROTEM Velocity Curves. A Prospective Observational Pilot Study | Ecaterina Scarlatescu | Received |
PB-303 | Increase in Plasma Stability and Thrombolytic Efficacy of pro-UK by Chemical Modification of its Arginine Residues | Liliya Mukhametova | Received |
PB-307 | Gender Differences in TAFI Regulation in Some Disorders | Eugene Roitman | Received |
PB-309 | The Role of Plasminogen Activator Inhibitor-1 (PAI-1) Levels and PAI-1 4G/5G Polymorphism in the Outcome of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients | Zsuzsa Bagoly | Received |
PB-314 | Different Pattern of Platelet Binding to Monocytes in Healthy Volunteers and in Patients with Coronary Artery Disease | Marina Loguinova | Received |
PB-315 | Pharmacological Actions of Inosine in a Hypercholesterolemic Model: Is It a New Antiatherosclerotic Drug? | Gabriel Ferreira Lima | Received |
PB-316 | Cement Dust Exposure Associated with Anaemia, Increased Platelets, Cardiac Markers and Dyslipidamia among Male Cement Workers in Calabar, Nigeria | Ifeyinwa Maryann Okafor | Received |
PB-317 | Hyperhomocysteinemia and endothelial Dysfunction of the Athletes in the Arctic Region | Nadezda Vorobyeva | Received |
PB-318 | Folate Deficiency of the Nenets of the Arctic Regions of the Russia | Nadezda Vorobyeva | Received |
PB-322 | Recombinant Human Soluble Thrombomodulin Protects Vascular Endothelial Cells from Radiation-induced DNA Damage | Takayuki Ikezoe | Received |
PB-324 | Ubiquitin-driven p38 Inflammatory Signaling Induced by Protease-activated Receptors | Joann Trejo | Received |
PB-326 | The Anti-coagulant Vitamin K-dependent Factor, Protein S, Alters Endothelium Functions by Regulating Multiple Vascular Permeability Related Signaling Pathways | Omar Benzakour | Received |
PB-327 | Simultaneous Assessment of sE-Selectin, Platelet Count and Mean Platelet Volume as Biomarkers for Pre-eclampsia | Maha Othman | Received |
PB-330 | Comparison of Syndecan-1 Levels as a Marker of Endotheliopathy in Thermal Injury and Blunt Trauma | Robert Ball | Received |
PB-332 | Ceramide 1 Phosphate Protects Human Endothelial Colony Forming Cells from Apoptosis and Increase Their Angiogenic Responses | Hebe Agustina Mena | Received |
PB-333 | Ticagrelor Induces the Expression of the Endothelial Phenotype CD34+ Progenitor Cells in the Presence of ADP via an Adenosine-mediated Mechanism | Alexandros D. Tselepis | Received |
PB-334 | Coxsackievirus B3 Replicates in Endothelial Colony Forming Cells and Inhibits Angiogenesis | Paula Romina Zubiry | Received |
PB-335 | Circulating Progenitor and Mature Endothelial Cells in Patients with Venous Thromboembolic Disease | Sofia Grille | Received |
PB-337 | PAR-1 Inhibition Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Endotoxemia | Christian Schoergenhofer | Received |
PB-340 | Type I Interferons Upregulate IFITM3 in Human Platelets and Megakaryocytes to Control Viral Infectivity | Robert Campbell | Received |
PB-341 | Sphingosine 1-phosphate Induces COX-2/PGE2 Expression via PKCalpha-mediated MAPKs and NF-kappaB Cascades in Human Cardiac Fibroblasts | Chuen-Mao Yang | Received |
PB-342 | Utility of New Red Cell Parameters for Identifying Functional Iron Deficiency and Anemia in Patients with Familial Mediterranean Fever | Zühre Kaya | Received |
PB-343 | The Role of Cytokines in the Development of Acquired Aplastic Anemia | Inna Berger | Received |
PB-346 | Hemoglobin-activated Platelet Regulates Macrophage Polarization under Hemolytic Conditions | Rashi Singhal | Received |
PB-350 | Circulating Cholesterol Containing, Platelet-derived Microparticles Contribute to the Procoagulant State Observed in Systemic Lupus Erythematosus | Shuaishuai Hu | Received |
PB-352 | Circulating Microparticles Improve Thrombin Generation and Fibrin Formation in Factor VIII Deficiency Plasma | Jovan Antovic | Received |
PB-356 | Delayed Initiation and Inadequate Anticoagulation as Independent Risk Factors for Development of Post Thrombotic Syndrome (PTS) - An Observational Study from a Tertiary Care Hospital in North India | Vikas Suri | Received |
PB-357 | Mitofusin 2 Regulates Mitochondria in Megakaryocytes, and Hemostasis and Thrombosis in Mice | Jesse W. Rowley | Received |
PB-358 | PDK1 Is Crucial to Pro-platelet Formation and Thrombopoiesis by Regulating MK Actin Polymerization | Sascha Geue | Received |
PB-359 | Unique Megakaryocytes from Human Adipose-derived Mesenchymal Stromal/stem Cell Line: Comparison with Hematopoietic Stem Cell-derived Megakaryocytes | Yukako Ono-Uruga | Received |
PB-360 | Nucleic Acid-based Therapeutic Targets for Protein S Deficient Patients | Ross Baker | Received |
PB-361 | Structural Insights during the Recognition of Endothelial Cell Protein C Receptor to the Protein C/activated Protein C in Presence of Phospholipid within EPCR Groove | Ramesh Prasad | Received |
PB-362 | Retrospective Study about using Bridging Therapy with Sodium Bemiparin in our Center | Pablo Romero Garcia | Received |
PB-364 | Betrixaban: Impact on Routine and Specific Coagulation Assays - A Practical Laboratory Guide | Romain Siriez | Received |
PB-366 | Inhibition of Factor XII is Antithrombotic in a Primate Model of Extracorporeal Membrane Oxygenation | Michael Wallisch | Received |
PB-367 | Effects of SERPINC1, PROC, PROS1 and EPCR Polymorphisms on the Risk of Venous Thromboembolism and Myocardial Infarction in Young Individuals | Zsuzsanna Bereczky | Received |
PB-368 | Structural and Functional Study of Naringin Octasulfate (NOS) on Human Antithrombin and Probing its Role in Thrombus Reduction using Rat Model | Irshad Ahmad | Received |
PB-372 | Emicizumab Impact on Factor VIII Inhibitor Determination in Plasma Samples from Persons with Hemophilia A (PwHA) using a New Kit for Modified Nijmegen-Bethesda Assay (MNBA) | Ali Sadeghi-Khomami | Received |
PB-375 | Data of Real-life Anticoagulant Treatment with Edoxaban In Patients with Atrial Fibrillation and Patients with Secondary Prevention of Deep Vein Thrombosis. Experience of Thirteen Months in our Center | Almudena Garcia Ruiz | Received |
PB-376 | Cross-sectional Survey of Minor Bleeding Rates in Children Prescribed Warfarin | Nadia Poci | Received |
PB-377 | Antithrombin Levels in Nigerians with Type2 Diabetes | Omolade Augustina Awodu | Received |
PB-378 | Laboratory Algorithm of Diagnostic of Hemorrhagic Diseases in Patients with Isolated Prolonged Activated Partial Thromboplastin Time (APTT) | Valeriia Krasivska | Received |
PB-379 | From Tissue Factor to Thrombin to Fibrin under Whole Blood Flow: Thrombin Makes Fibrin but Fibrin Quenches Thrombin | Scott Diamond | Received |
PB-380 | Effect of Andexanet-tissue Factor Pathway Inhibitor (TFPI) Interaction on in vitro Clot Formation and Lysis via Different Coagulation Pathways | Genmin Lu | Received |
PB-382 | Molecular Sequencing of Factor VII Variants through Collaborative Advocacy for Families in the United States: 154 Individuals Using Multi-gene Next Generation Panel | Diane Nugent | Received |
PB-383 | Inappropriate Use of Fresh Frozen Plasma in a Tertiary Care Hospital | Sidra Asad Ali | Received |
PB-385 | Clot Waveform Analysis: Determination of Optimal Wavelength to Assess the Fibrin Coagulation Process | Jonathan Evrard | Received |
PB-387 | Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia - An Experience fom Resource Constraint Country | Nida Anwar | Received |
PB-389 | eNOS, ACE AND PAI-1 Gene Polymorphisms in a Sample of General Population of Northern Greece | Androniki Papoutsi | Received |
PB-391 | Association between Factor V Leiden and APCR Values: Data from a Portuguese University Hospital | Analia Carmo | Received |
PB-393 | Prevalence of Common Genetic Variants Associated with Thrombophilia in Asymptomatic young Individuals with a Family History of Thrombosis | Androniki Papoutsi | Received |
PB-394 | Identification and Differentiation of Coagulation Factors in Prothrombin Complex Concentrates (PCC´s) | Maurice Mandago | Received |
PB-398 | FXIa Binds and Forms a Complex with Plasminogen Activator Inhibitor-1 that Inhibits Its Activity and Induces Internalization and Degradation by Endothelial Cells | Anh Ngo | Received |
PB-402 | Saliva-derived Tissue Factor Induces Thrombin Generation in a Diurnal Rhythm | Lisa N. van der Vorm | Received |
PB-403 | Activated Factor VII Fused with Transferrin Showed Prolonged Half-life with Safe Toxicity Profile in Animal Models | InYoung Song | Received |
PB-404 | "Real World" Usage of Prothrombin Complex Concentrates (PCCs) to Correct Coagulopathy. A 3 Year Retrospective Review in an Academic Hospital System | Ismini Kourouni | Received |
PB-405 | Gene Expression of Coagulation Factors after Experimental Snake Envenomation in Mice | Marcelo Larami Santoro | Received |
PB-406 | Enhanced FIX Collagen IV Binding Shows Improved Hemostatic Effects in a Hemophilia B Mouse Model | Davide Matino | Received |
PB-408 | Factor XI Level Is a Determinant of Plasma Clot Growth | Cornelis Kluft | Received |
PB-409 | Robustness of Spatial Thrombin Generation and Fibrin Clot Propagation | Anna Kuprash | Received |
PB-410 | The Blood Clot is Covered by a Fibrin Film that Protects against Microbes | Fraser Macrae | Received |
PB-411 | Binding of Coagulation Factor XIII Zymogen to Activated Platelet Subpopulations: Roles of Integrin aIIbß3 and Fibrinogen | Nadezhda Podoplelova | Received |
PB-412 | Presence and Function of Cellular Factor XIII in Human Cornea | Zsuzsanna Z. Orosz | Received |
PB-413 | The Effect of Factor XIII Levels on the Incorporation of a2-plasmin Inhibitor into Fibrin Clots: Association with the Therapeutic Outcome of Acute Ischemic Stroke Patients | Zsuzsa Bagoly | Received |
PB-415 | Fibrin Fiber Mechanical and Structural Properties Are Altered in Individuals with Cardiovascular Disease on Low/Medium Dose Aspirin | Martin Guthold | Received |
PB-416 | Factor XIII Concentrate Can Improve Clot Stabilization Guided by Thromboelastometry in Patient with Liver Disease: A Case Report | Tomaz Crochemore | Received |
PB-418 | Plasma Fibrinogen Concentration As an Acute Marker of Myocardial Infarction | Chinedu Kingsley Dike | Received |
PB-419 | Apixaban Does Not Generate False-positive dRVVT Interpretations for Lupus Anticoagulants, Even at Peak Levels | Osamu Kumano | Received |
PB-422 | Antiphospholipid Syndrome: Maternal and Perinatal Outcome after Treatment in Next Pregnancy. Retrospective Analysis | Beatriz Grand | Received |
PB-423 | Are IgM Antiphospholipid Antibodies Redundant in the Classification Criteria for the Antiphospholipid Syndrome? | Walid Chayoua | Received |
PB-424 | A Single-arm Pilot Feasibility Cohort Study of Rivaroxaban in Antiphospholipid Syndrome | Mark Crowther | Received |
PB-426 | Use of Direct Oral Anticoagulant in Antiphospholipid Syndrome: Systematic Review of Literature | Denis Wahl | Received |
PB-431 | Evaluation of Lupus Anticoagulant Testing: A Descriptive Single Centre Experience | Sergio Felipe Pinzon Marińo | Received |
PB-433 | A Comparison between Mixing Test Specific Cut-off and the Index of Circulating Anticoagulant with Multiple APTT and dRVVT in Specificity for Lupus Anticoagulant | Osamu Kumano | Received |
PB-434 | Thrombotic Risk Assessment in Antiphospholipid Syndrome | Analia Carmo | Received |
PB-436 | Recent Metods for Laboratory Detection of Lupus Anticoagulant in Patients with Antiphospholipid Syndrome | Valeriia Krasivska | Received |
PB-439 | Direct Oral Anticoagulants in Venous Thromboembolic Disease; Boon or Bane? | Andrea Ang | Received |
PB-440 | Outcomes in Non-valvular Atrial Fibrillation Patients with Good and Poor INR Control after Switching to Direct Oral Anticoagulants | Scott Kaatz | Received |
PB-441 | PK/PD (Thrombinography and Fibrinography) Response Variability to Rivaroxaban in Patients Aged 80 Years and Older with Atrial Fibrillation: Results of the ADAGE Study | Geoffrey Foulon | Received |
PB-442 | Health-related Quality of Life after Pharmacomechanical Catheter-directed Thrombolysis for Proximal Deep Vein Thrombosis | Susan R. Kahn | Received |
PB-443 | DTI/DXI Interferences with Global Coagulation Tests in Daily Care Emergency Admissions - Results of the Prospective DRESDEN NOAC REGISTRY (NCT01588119) | Jan Beyer-Westendorf | Received |
PB-444 | Evaluation of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of the Anti-factor XI Antibody, AB023, in Healthy Adult Volunteers | Christina U. Lorentz | Received |
PB-445 | The Indirect Effects of Dabigatran En Rivaroxaban on Fibrinolysis | Suzanne Zwaveling | Received |
PB-446 | Risk of Thrombosis and Bleeding in Patients Treated with Warfarin or Apixaban for Non-valvular Atrial Fibrillation: A Large, National, Retrospective Study | Matthew Wanat | Received |
PB-447 | Novel Universal Antidote to Non-Vitamin K Antagonist Anticoagulants | Georges Jourdi | Received |
PB-448 | Comparing the Proportions of Patients that Meet Criteria for Extended Prophylaxis with Betrixaban Based on APEX Trial and FDA Indication | Scott Kaatz | Received |
PB-449 | Reversal of Direct Factor Xa Inhibitor-Associated Major Bleeding with Four-factor Prothrombin Complex Concentrate: A Systematic Review and Meta-analysis | Siavash Piran | Received |
PB-450 | Resumption of Anticoagulant Therapy after Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-analysis | Derek Little | Received |
PB-452 | Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Treated with Vitamin K Antagonists or Rivaroxaban | Maria Abbattista | Received |
PB-454 | Variable Response in Individuals to Rivaroxaban and Apixaban over Time | Suzanne Zwaveling | Received |
PB-455 | Effect of Anti-arrhythmic Medication Drug Interactions on Thrombotic and Bleeding Outcomes in Patients with Atrial Fibrillation | Matthew Wanat | Received |
PB-456 | Lean Body Weight is the Best Scale for Venous Thromboprophylaxis Algorithm in Severely Obese Patients Undergoing Bariatric Surgery | Corinne Frere | Received |
PB-458 | Post Analytical External Quality Assessment of Anticoagulant Dosing for Warfarin Therapy | Dianne Kitchen | Received |
PB-459 | Creation of an Algorithm for Predicting Doses of Warfarin < 17.5mg Using CYP2C9 and VKORC1 Polymorphisms and Non-genetic Factors | Maria Auxiliadora Parreiras Martins | Received |
PB-460 | Warfarin Use Increases Bleeding Risk in Hemodialysis Patients with Atrial Fibrillation: Evidence from Meta-analysis Using Real World Data | Salman Hussain | Received |
PB-461 | Change of Rivaroxaban Anticoagulant Effect during the 24 Hours | Olesya Matvienko | Received |
PB-463 | Flow Based Analysis of Heparin Inhibition of VWF Dependant Platelet Capture | Amita Ranger | Received |
PB-465 | Real-world Experience of Direct Oral Anticoagulants Use in North Melbourne, Australia | Hui Yin Lim | Received |
PB-466 | Relationship between Dabigratan Concentrations in Plasma and Results of Routine Coagulation Assays PT, APTT, TT and Fibrinogen | Sandra Margetic | Received |
PB-467 | Measuring Anti-factor Xa Levels to Monitor Enoxaparin in Pregnant Women: A Prospective Comparative Study | Fahad Aleidan | Received |
PB-468 | Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation in Clinical Practice: Outcomes from the First Observational and Prospective Study in Spanish Population | Maria Cerdá Sabater | Received |
PB-470 | Multihospital System Implementation of the Anti-Xa for Titration for Monitoring Unfractionated Heparin (UH) Therapy | Paul Lindholm | Received |
PB-471 | Correcting Inappropriate Prescribing of Direct Oral Anticoagulants: A Population Health Approach | Geoffrey Barnes | Received |
PB-472 | Impact of Rivaroxban on Platelet Reactivity and von Willebrand Factor Antigen and Activity in Patients with Venous Thrombosis | Nina Schultz | Received |
PB-473 | Weekly Warfarin Maintenance Dose According to Variations in Four Genes Evaluated in Patients Assisted at a Brazilian Anticoagulation Clinic | Maria Auxiliadora Parreiras Martins | Received |
PB-477 | Development, Implementation and Evaluation of Application for Monitoring Oral Anticoagulant Therapy | Maria Auxiliadora Parreiras Martins | Received |
PB-479 | A Multicenter Experience with Idarucizumab "in Real World" as Reversal Anticoagulation of Dabigatrán | Marta Villalba Montaner | Received |
PB-481 | Retrospective Observational Study of Patients Treated with Rivaroxaban in Saudi Arabia | Muhammad Riazuddin | Received |
PB-483 | Description and Evaluation of the Comparison of Activated Partial Thromboplastin Time versus Anti-factor Xa Activity for Therapeutic Unfractionated Heparin Monitoring in a Tertiary Academic Medical Center using Three Different Adult Weight-based, Nurse Ma | Laura Talamo | Received |
PB-484 | Idarucizumab for Reversing Anticoagulation in Patients Treated with Dabigatran: Experience in our Center | Estefania Morente Constantin | Received |
PB-485 | Warfarin Dose Requirements in Patients with Heart Diseases Assisted at an Anticoagulation Clinic in the Southeast Brazil | Maria Auxiliadora Parreiras Martins | Received |
PB-486 | Direct-acting Oral Anticoagulant Drug Level Monitoring in Clinical Patient Management | Batia Roth | Received |
PB-487 | Establishment of a Centralized Monitoring System for Patients Receiving Anticoagulant Therapy in the Arkhangelsk Region Russia | Nadezda Vorobyeva | Received |
PB-488 | Evaluation of Algorithms for Warfarin Dose Prediction | Maria Auxiliadora Parreiras Martins | Received |
PB-489 | Development of an Educational Intervention Focused on Low-income Population Treated with Warfarin | Maria Auxiliadora Parreiras Martins | Received |
PB-491 | Direct Oral Anticoagulant Use in Obese Patients: Preliminary Results of a Pilot Study | Laura Talamo | Received |
PB-492 | Arterial Thrombosis Depends on Shear Rate More Than Shear Rate Gradient | David Ku | Received |
PB-493 | Increased Platelet Count and Reticulated Platelets in Recently Symptomatic versus Asymptomatic Carotid Artery Stenosis and in Cerebral Microembolic Signal-negative Patient Subgroups: Results from the HEIST Study | Stephen Murphy | Received |
PB-495 | Significance of Single Nucleotide Polymorphisms (SNPs) within Genes Encoding Platelet Glycoprotein Receptors in Patients with Infective Endocarditis (IE) | Mariia Sorokina | Received |
PB-496 | Risk Factors for Brain Vessels´s ?hrombosis/Stenosis in Young Patients with Ischemic Stroke | Tsvetomir Tsvetanov | Received |
PB-497 | In vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions | Jonathan Douxfils | Received |
PB-500 | Resonance Raman Spectroscopy as a Tool to Study Blood Flow in Brain Vessels in vivo | Evelina I. Nikelshparg | Received |
PB-501 | Assessing Three-dimensional Fibrin Polymerization Dynamics during Heparin Administration and Protamine Reversal in Cardiac Surgical Patients | Diane Malu Tshikudi | Received |
PB-503 | Ir-CPI: An Original Inhibitor of Thrombosis and Thrombosis-associated with Cancer | Edmond Godfroid | Received |
PB-505 | Effectiveness and Safety of Rivaroxaban versus Low Molecular-weight Heparin for Treatment of Cancer-associated Thromboembolism | Craig I. Coleman | Received |
PB-506 | Optimizing Therapy for Venous Thromboembolism in Multiple Myeloma: A Systematic Review | Samuel Abegunde | Received |
PB-508 | Comparative Efficacy and Safety of Anticoagulation for the Treatment of Cancer-associated Thrombosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials | Craig I Coleman | Received |
PB-509 | A Monoclonal Antibody to Human Podoplanin Inhibits Human Platelet Aggregation Induced by Tumor Cells | Yiming Zhao | Received |
PB-510 | D-dimer Levels for Prediction of Symptomatic Central Venous Catheter-related Thrombosis in Breast Cancer Patients | Ilham Benzidia | Received |
PB-511 | Hypercoagulation Screening as Tool for Cancer Diagnosis: An Update on Tumor Incidence and Risk Factors in the HYPERCAN Study | Sara Gamba | Received |
PB-513 | Cost-effectiveness of Edoxaban versus Dalteparin for Treatment of Cancer-associated Thrombosis | Nathan Connell | Received |
PB-514 | Non-phosphorylated and Phosphorylated Signal Transduction Peptide (STP) of Tissue Factor (TF) in Urine Are Potential Biomarkers for Bladder and Colon Cancer | Robert Greenfield | Received |
PB-516 | Leucocyte and Platelet Activation in Patients with BCR-ABL Negative Myeloproliferative Disorders | Charlene Portelli | Received |
PB-519 | Evaluation of Risk Factors and Assessment Models for Predicting Venous Thromboembolism in Lung Cancer Patients | Joanna Rupa-Matysek | Received |
PB-520 | Splanchnic Thrombosis Associted to Myeloproliferative Neoplasms: A Cohort of 233 Tunisian Patients | Hadef Skouri | Received |
PB-521 | The Effect of Hydroxyurea on Blood Coagulation in Sickle Cell Disease | Munira Borhany | Received |
PB-522 | The Effect of Inflammatory Cytokines IL-6, IL-10, IL-1b and TNFa on Thromboelastography Parameters in Pediatric Patients with Acute Lymphoblastic Leukemia | Saskia Prasca | Received |
PB-524 | Clinical and Global Hemostatic Parameters in Patients with JAK2 V617F Mutation Myeloproliferative Neoplasms (MPNs) | Aimwipa Sasakul | Received |
PB-525 | Generation of Neo-epitopes on Hypochlorous Acid-modified Human Antithrombin: An Immunological Study | Parvez Ahmad | Received |
PB-527 | The Usefulness of Standard and Derived ROTEM Parameters for DIC Prediction in Septic Patients | Ecaterina Scarlatescu | Received |
PB-528 | Recombinant A2 Domain of von Willebrand Factor Attenuates Microthrombi Formation, Organ Injuries and D-dimer Levels in a Porcine Model of Methicillin-resistant Staphylococcus Aureus (MRSA) Sepsis-induced Disseminated Intravascular Coagulation (DIC) | Miguel Cruz | Received |
PB-529 | The Expression of Tissue Factor between Monocyte Subsets: A Role in Sepsis-associated Coagulopathy? | Kathryn Mary Musgrave | Received |
PB-530 | Added Value of the DIC Score and of D-dimer to Predict Outcome after Successfully Resuscitated Out-of-Hospital Cardiac Arrest | Nina Buchtele | Received |
PB-532 | Evaluation of the Effectiveness of AT III Concentrate in Acute DIC-syndrome | Nadezda Vorobyeva | Received |
PB-533 | von Willebrand Factor Interactions with Platelets and Leukocytes is Critical for Obesity-mediated Venous Thrombosis | Alison Michels | Received |
PB-534 | Iron Deficiency Increases Platelet Procoagulant Capacity in a Ferric Chloride Model of Arterial Thrombosis | Kristine Jimenez | Received |
PB-541 | A Highly Efficient and Adhensive Antibacterial Dextran Derivative for Rapid Hemostasis with Wound Healing | Chunyu Liu | Received |
PB-543 | Normal to High Anti-Xa Levels in High Body Weight Patients Using Apixaban and Rivaroxaban | Zahra Mahir | Received |
PB-544 | Global Coagulation Assay Changes in Patients with Chronic Renal Impairment | Hui Yin Lim | Received |
PB-545 | Assessment of the Agreement between the International Normalised Ratio (INR) Values Obtained by Applying Two Different Reagent/Instrument Combinations | Alicia Noemi Blanco | Received |
PB-547 | The Coagulation System State in Patients with Philadelphia-negative Myeloproliferative Neoplasms | Olesya Matvienko | Received |
PB-548 | Thromboelastographic Changes in Patients with BCR-ABL Negative Myeloproliferative Disorders | Marie Claire Cini | Received |
PB-549 | The Impact of Age, Ethnicity and Gender on Global Coagulation Assays | Hui Yin Lim | Received |
PB-551 | Identification of Protein C System-associated Thrombophilia using an Endothelial Cell-based Thrombin Generation Assay | Ali Amirkhosravi | Received |
PB-554 | A Rapid Fully-automated Chemiluminescent Immunoassay for the Early Quantification of ADAMTS13 Activity in TTP Diagnosis | Carla Valsecchi | Received |
PB-555 | Urgent Laboratory Investigation of HIT Syndrome with an Automated Immunoassay in Cardiovascular Patients | Theodora Kostelidou | Received |
PB-556 | Platelet Hyporeactivity Combined with Enhanced Coagulation in Healthy Term and Preterm Newborns During First Days of Life | Ekaterina Koltsova | Received |
PB-557 | Von Willebrand Factor Antigen Levels Predict Major Adverse Cardiovascular Events in Patients with Asymptomatic Carotid Stenosis | Katarina D. Kovacevic | Received |
PB-558 | Thrombin Generation in Real-world Patients Treated with Two Different Doses of Apixaban | María De Lourdes Herrera | Received |
PB-560 | Active von Willebrand Factor Levels in Kidney Disease Are Associated with Disease Severity and Type of Dialysis | Lisa N. van der Vorm | Received |
PB-561 | Role of Thromboelastography to Assess Thrombin Generation in Acute Coronary Syndrome (ACS) | Qiuya Lu | Received |
PB-563 | Laboratory Assessment of Dabigatran Levels and Anti-Xa Anticoagulant Levels | Ivanka Paskaleva | Received |
PB-566 | Natural Anticoagulant Deficiencies in Thais: A Population-based Study | Ponlapat Rojnuckarin | Received |
PB-567 | Changes in Tissue Factor Concentration and APTT in Haemolysed and Non-haemolysed Paired Citrate Samples | Kieron Hickey | Received |
PB-569 | DOAC Filter Effect on Thrombin Generation: Pre-analytical Considerations and Analytical Perspectives | Damien Gheldof | Received |
PB-570 | Heparin-induced Thrombocytopenia: An International Assessment of the Quality of Laboratory Testing | Zachary Liederman | Received |
PB-571 | A Comparison of Two Point-of-Care Testing Platforms (CoaguchekŽ Pro II and CoaguchekŽ INRange) to Standard Laboratory Measurement of the International Normalised Ratio | Shu Hui Yeang | Received |
PB-572 | Measurement of Coagulation Factors during Rivaroxaban and Apixaban Treatment: Results from Two Crossover Trials | Luuk J.J. Scheres | Received |
PB-573 | Stability of Thrombin Generation and Thrombin Dynamics in Healthy Individuals over a One-year Period | Joke Konings | Received |
PB-574 | The Association of Hereditary Thrombophilia with Clinically Relevant Hypercogulation State and Free Flap Thrombosis in Microvascular Surgery | Karina Drizlionoka | Received |
PB-575 | Use of a Liquid Recombinant Thromboplastin (DG-PT RecombiLIQ, Diagnostic Grifols) for Monitoring Vitamin K Antagonist Therapy | Anita Woolley | Received |
PB-576 | Heparin Anti-Xa Assay versus Activated Partial Thromboplastin Time to Monitor Unfractionated Heparin during Extracorporeal Membrane Oxygenation | Deepa Jayakody Arachchillage | Received |
PB-577 | An Automated Modified Anti-Xa Assay for the Potency Assessment of Bemiparin in Pharmaceutical Formulations | Alejandra Scazziota | Received |
PB-580 | Limits to Sensitivity of 4T Score for Heparin Induced Thrombocytopenia | Deepa Jayakody Arachchillage | Received |
PB-581 | External Quality Assessment of Point of Care Testing in Haemostasis | Shelene Munroe-Peart | Received |
PB-582 | Clot Waveform Analysis for Measuring and Quantifying Fibrin Clot Formation | Jonathan Evrard | Received |
PB-583 | The Calibrated Automated Thrombography in Patients with Factor XII Deficiency | Natalya Silina | Received |
PB-584 | Thrombin Generation Analysis with a New Automated System (ST-Genesia): Inter-series Performances during DRIVING Study and Comparison with CAT System | Virginie Siguret | Received |
PB-586 | D-dimer Measurement: Lipid Interference Removal through High-speed Centrifugation | Audrey Carlo | Received |
PB-588 | Development of a HPLC-UV Method for the Measurement of Dabigatran from Plasma and its Application as Reference Method for the Evaluation of a Novel Chromogenic Dabigatran Assay | Anita Kuruczné Kern | Received |
PB-589 | Fibrinolysis System and Combined oral Contraceptives | Nadezda Vorobyeva | Received |
PB-591 | Reference Change Value for INR: A Simple Tool for Management of Patients on Oral Anticoagulation | Alejandra Scazziota | Received |
PB-593 | Reproducibility of RotemŽ Device | Erica Scalambrino | Received |
PB-594 | Taipan Snake Venom Time Detects the Lupus Anticoagulants in Anticoagulated, Triple-positive Antiphospholipid Syndrome Patients | Gary William Moore | Received |
PB-596 | Improving Lupus Anticoagulant Testing with 2 New APTT and dRVVT Reagents | Corinne Frere | Received |
PB-598 | Validation of an Automated Algorithm for Interpretation of Lupus Anticoagulant Testing on Stago STA-R Max | Lisa Florin | Received |
PB-599 | Thrombin Generation Test in Detection of Prothrombotic Phenotype in Asymptomatic Carriers of the FV G1691A or/and FII G20210A Mutations | Olesia Matvienko | Received |
PB-600 | Management of Direct Oral Anticoagulants for Low-bleeding Risk Surgery: The Example of Cataract Surgery | Anne Godier | Received |
PB-601 | Using Drug Levels to Guide Peri-operative Management of Direct Oral Anticoagulants Prior to Emergency Orthopaedic Surgery; Experience from a Large Teaching Hospital within the UK | Emily Millen | Received |
PB-603 | Antithrombin Levels Less than 60% Lead to Reduced Anti-Xa Levels | Claire Pillion | Received |
PB-605 | Inpatient to Outpatient Transition of Care for Pediatric Patients with Venous Thromboembolism | James Munn | Received |
PB-606 | Cerebral Sinovenous Thrombosis (CSVT) in Children: 25 Years Single-center Prospective Pediatric Cohort in Argentina | Gabriela Sciuccati | Received |
PB-607 | Significance of GPIba -5T>C, GPIba VNTR, GPVI T13254C Polymorphisms and HPA-2 in the Etiology of Pediatric Arterial Ischemic Stroke | Desiree Coen Herak | Received |
PB-610 | D Dimer Levels and Thrombosis in Children with Systemic Lupus Erythematosus | Jasmina Ahluwalia | Received |
PB-611 | Anti-factor H Autoantibody-associated Hemolytic Uremic Syndrome in an Argentinean Pediatric Cohort | Célia Dos Santos | Received |
PB-613 | Prosthetic Valve Thrombosis in Children | Patricia Kewada | Received |
PB-614 | Towards a Consensus for Standardized Assessment of Pediatric Patients with Vascular Malformations (VM) at Risk for Coagulopathy | Leonardo Brandao | Received |
PB-616 | Dosing, Safety and Efficacy of Therapeutic and Prophylactic Low Molecular Weight Heparin in the Pediatric Population: A Systematic Review | Irene Lisette Maria Klaassen | Received |
PB-617 | Exploring Adolescent´s Perceptions and Emotional Reaction to Thrombosis and Anti-coagulant Therapy: A Qualitative Study | Tina Biss | Received |
PB-621 | How do Adolescents Experience Anticoagulant Adherence? A Qualitative Exploration of the Barriers and Facilitators | Kay Anne Rooney | Received |
PB-624 | Spontaneous Thrombosis in a Patient With Factor XI Deficiency Homozygous for the p.Cys398Tyr Mutation | Utku Aygüne | Received |
PB-626 | The Joint Effect between Different Types of Combined Oral Contraceptives and Genetic Risk Factors on Venous Thrombosis Risk: Results from the MEGA Case-control Study | Deeksha Khialani | Received |
PB-627 | Risk of Recurrent Venous Thromboembolism in Pregnancy and Postpartum Period: Results from the MEGA Follow-up Study | Luuk J.J. Scheres | Received |
PB-628 | Misuse of Low Molecular Heparin in Pregnancy | Julija Samonikov Tosevska | Received |
PB-629 | Written Alert System Improves Thromboprophylaxis Compliance in Caesarean Women | Cecilia Guillermo | Received |
PB-631 | Management of Venous Thromboembolism (VTE) during Pregnancy and Post-partum: Findings from the Indian Subset of an International, Observational Study (SAVE) | Ravi Mohan Tiwari | Received |
PB-632 | Thrombin Generation and Adverse Pregnancy Outcomes | Irina Gribkova | Received |
PB-634 | Reduced Protein C Global Assay Level in Infertile Women with IVF Failure: A Pilot Study | Hanan azzam | Received |
PB-635 | Hereditary Thrombophilia Assessment in Pregnancy | Tatjana Makarovska Bojadzieva | Received |
PB-636 | Localization and Massiveness of Thrombosis in Women with Pregnancy Related Thrombosis Compared to Women with Unprovoked Venous Thromboembolism | Predrag Miljic | Received |
PB-637 | Prospective Study of Changes in Haemostasis in High-risk Pregnancy | Lucia Stanciakova | Received |
PB-638 | Risk Assessment of Venous Thromboembolism (VTE) during Pregnancy and Post-partum: Findings from the Indian Subset of an International, Observational Study (SAVE) | Ravi Tiwari | Received |
PB-639 | Genetic Risk Factors of Endothelial Dysfunction in Pregnant Women | Natalya Silina | Received |
PB-640 | Characterization and Outcomes of aTTP Patients with Initial or Recurrent Disease: Experience from the Phase III HERCULES Trial of Caplacizumab | Hilde De Winter | Received |
PB-641 | Efficacy and Safety of Open-label Caplacizumab in Patients with Exacerbations of Acquired Thrombotic Thrombocytopenic Purpura during the Phase III HERCULES Study | Filip Callewaert | Received |
PB-642 | Treatment of Acquired TTP with the Anti-vWF Nanobody, Caplacizumab, Results in a Significant Reduction in Healthcare Resource Utilization - Data from the Phase III HERCULES Trial | Filip Callewaert | Received |
PB-644 | Initial Clinical Presentation of Thrombotic Thrombocytopenic Purpura with Focal Stroke: A Series of Patients from the French National Reference Center Registry for Thrombotic Microangiopathies | Maxime Delrue | Received |
PB-645 | Provision of an External Quality Assessment for ADAMTS13 | Ian Jennings | Received |
PB-647 | Pre-test Likelihood of ADAMTS13 Severe Deficiency in the Context of Thrombotic Microangiopathies: Validation of the PLASMIC Score in a Southern Italy Hospital | Elvira Grandone | Received |
PB-648 | "How we Treat": Recurrent TTP Patients Undergoing Elective Surgery | Sara Arcudi | Received |
PB-652 | Identification of Novel ADAMTS13 Gene Mutation in a Patient with Congenital Thrombotic Thrombocytopenic Purpura | Anila Rashid | Received |
PB-654 | Evaluation of Hospital Readmissions among Patients Hospitalized for Acute Medical Illness and at Risk for Venous Thromboembolism in the US | Richey Neuman | Received |
PB-655 | Comparison of the Risk of Recurrence in Patients with Venous Thromboembolism (VTE) Provoked by Major and Minor Surgery and Trauma | Tiago Gregorio | Received |
PB-656 | Comparative Thrombosis Risk of Vascular Access Devices among Critically Ill Medical Patients | Scott M Stevens | Received |
PB-657 | Cost-effectiveness of Betrixaban Compared with Enoxaparin for Primary Venous Thromboembolism Prophylaxis in Hospitalised Acute Medically Ill Patients in the United States | Andrea Hafeman | Received |
PB-658 | Venous Thromboembolism Clinical Risk Assessment Model for Patients with a Lower Limb Trauma Requiring Immobilization: The TIP Score | Pierre-Marie Roy | Received |
PB-660 | A Single Center Analysis of Pre-, Intra- and Post-operative Thrombotic Events in a Cohort of 470 Orthotopic Whole Liver Transplantations | Nicoletta Riva | Received |
PB-661 | miRNA Expression Profile in Venous Thrombosis Disease: Results from the Genetic Analysis of Idiopathic Thrombophilia Project | Alba Rodriguez-Rius | Received |
PB-662 | Clinical Characteristics and Outcome of Patients with Subsegmental Pulmonary Embolism | Farčs Moustafa | Received |
PB-663 | Assessment of General Awareness of Thrombosis and How Best to Communicate this Information | Ann Marie O´Neill | Received |
PB-664 | Postoperative Venous Thromboembolism Prophylaxis in Perioperative Trials of Tranexamic Acid: A Systematic Review and Meta-analysis | Joshua Taylor | Received |
PB-665 | Testosterone Therapy and Venous Thromboembolism: A Systematic Review and Meta-analysis | Damon E Houghton | Received |
PB-666 | Homozygotes in FXI rs 2289252 and ABO rs 8176719 Have a Low Risk of VTE Recurrence | Jan Kvasnicka | Received |
PB-667 | Risk of Pulmonary Embolism after Surgical Resection of Meningioma | Andrea Artoni | Received |
PB-668 | Lower-leg Injury Leads to a Procoagulant State | Carolina E. Touw | Received |
PB-670 | The Effect of Alpha-2 Plasmin Inhibitor Activity and Antigen Levels and p.Arg6Trp Polymorphism on the Risk of Venous Thromboembolism | Éva Katona | Received |
PB-671 | Risk Stratification for Prevention of Venous Thromboembolism in Hospitalized Medical Patients: Can Thromboprophylaxis in Hospitalized Medical Patients Be Safely Restricted to Reduce Costs? | Alison Mary Bond | Received |
PB-672 | Predictors of Venous Thromboembolism in Patients Undergoing Neurosurgery for Glioma | Marco Capecchi | Received |
PB-673 | IVSS Safety Zone Protocol vs Padua Score in the Prevention of Thromboembolic Disease in Medical Patients: A Comparative Prospective Study | Juan Serrano | Received |
PB-680 | 25mmHg vs. 35 mmHg Graduated Elastic Compression Stockings to Treat Acute Symptoms of Deep-Vein Thrombosis: The CELEST Double-blind Trial | Jean-Philippe galanaud | Received |
PB-681 | Individualized Prediction Model for Risk of First DVT Using Clinical Assessment and D-dimer | Sameer Parpia | Received |
PB-682 | Long-term Risk of Post-thrombotic Syndrome after Symptomatic Distal Deep-vein Thrombosis: The CACTUS-PTS Study | Jean-Philippe Galanaud | Received |
PB-683 | Age-adjusted versus Clinical Probability-adjusted D-dimer to Exclude Pulmonary Embolism | Scott M Stevens | Received |
PB-684 | Vena Caval Filters in Patients Presenting with Major Bleeding during Anticoagulation for Venous Thromboembolism | Farčs Moustafa | Received |
PB-685 | Whole Leg Ultrasound for the Diagnosis of Deep Vein Thrombosis Recurrence | Michelangelo Sartori | Received |
PB-688 | Clinical Predictors of Right Ventricular Dysfunction in Acute Pulmonary Thromboembolism | Jose Bonorino | Received |
PB-689 | Individualized Thromboprophylaxis in Patients with Lower-leg Cast Immobilization - A Validation and Subgroup Analysis in the POT-CAST Trial | Banne Nemeth | Received |
PB-690 | Prevalence of Pulmonary Embolism in Patients Presenting to the Emergency Department with Syncope in an Integrated Healthcare System | Scott S. Stevens | Received |
PB-693 | Assessment of D-dimer Value at First Venous Thromboembolism and Risk of Recurrence | Rosa Vidal | Received |
PB-695 | A Systematic Review to Determine Patient Preferences to Receive Thromboprophylaxis to Prevent Deep Vein Thrombosis and Pulmonary Embolism | Natasha Dembrey | Received |
PB-696 | Efficacy and Safety of Rivaroxaban and Apixaban in Relation to Low Molecular Heparin and Vitamin K Antagonists in Acute Venous Thromboembolism - A Single Center Prospective Study | Waldemar Wysokinski | Received |
PB-697 | Circulating Endothelial Cells as a New and Early Candidate Biomarker of Residual Pulmonary Vascular Obstruction after Pulmonary Embolism | Nicolas Gendron | Received |
PB-698 | Thrombophlebitis Post Varicose Vein Surgery: To Treat or Not to Treat? | Hui Yin Lim | Received |
PB-699 | Comparison of Risk Assessment Methods to Prevent Venous Thromboembolism (VTE) in Surgical Patients with Short Length of Hospital Stay | Maria Chiara Chindamo | Received |
PB-701 | Effectiveness and Safety of Outpatient Rivaroxaban versus Warfarin in Patients with Provoked Acute Venous Thromboembolism | Craig I Coleman | Received |
PB-702 | Rivaroxaban and Apixaban for Treatment of Acute Isolated Calf Deep Vein Thrombosis - A Single Center Prospective Study | Robert McBane | Received |
PB-704 | The Relationship between Neutrophil Lymphocyte Ratio and Deep Vein Thrombosis in Unilateral Limb Edema in Suspected Deep Vein Thrombosis Patients | Ikhwan Rinaldi | Received |
PB-705 | Application of an Explanatory Model for Emergency Physician Pulmonary Embolism Testing in a National Cohort | Sahar Zarabi | Received |
PB-706 | Deep Dive into DVTs: A 3 Year Retrospective Review of Patients with Deep Vein Thrombosis (DVT) on an Ambulatory Integrated Care Pathway (ICP) | V Graham | Received |
PB-707 | The Association of Characteristics of Central Venous Catheters with Venous Thrombotic Events in Pediatric Patients Undergoing Fontan Surgery | Ketan Kulkarni | Received |
PB-708 | Implementation of an Acute DVT Ambulatory Care Pathway in a Large Urban Centre: Current Challenges and Future Opportunities | Sarah Kelliher | Received |
PB-709 | Treatment Satisfaction with Rivaroxaban for the Management of Venous Thromboembolism (VTE) - Early Results from the ´Follow-up in Rivaroxaban Patients in Setting of Thromboembolism´ (FIRST) Registry | Victoria Speed | Received |
PB-711 | Evaluation of an Educational Video for Patients Taking Warfarin | Maria Auxiliadora Parreiras Martins | Received |
PB-712 | Subsegmental Pulmonary Embolism: An Innocent Bystander? | Myrthe Carlijn Gerritsen | Received |
PB-714 | Outpatient Management of Deep Vein Thrombosis using Direct Oral Anticoagulants is Safe and Cost-effective | Hui Yin Lim | Received |
PB-715 | Knowledge Derived from a Hospitalar Thromboprophylaxis Program | Maria Chiara Chindamo | Received |
18-21 July 2018 Dublin
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|